LONDON – 26 MAY 2026
This ticket gains you access to the 2026 Business of Cannabis Awards party at Rivington Street (8pm).
LONDON – 26-27 MAY 2026
Includes all Standard benefits plus premium upgrades: VIP lounge access, priority seating, concierge assistance, lunch on both days.
Complimentary access to BofC Awards Party.
LONDON – 26-27 MAY 2026
Final Release
4 for 3 — Final Release
VIP Experience
BoC Awards
Working with Prohibition Partners for Cannabis Europa has been an absolute pleasure. Their dedication, exceptional professionalism, and collaborative spirit have made a meaningful difference, and we sincerely value their support.
We were truly honoured to sponsor the VIP Lounge and be part of an event that continues to set the standard for meaningful dialogue and progress in the medical cannabis industry. We left feeling excited and optimistic about the future.
We’re reimagining the VIP experience at Cannabis Europa London this year — a forum created exclusively for senior stakeholders, policymakers and investors defining the European market.
VIP delegates will have access to a separate space with its own agenda, service team and communications, designed to sit alongside the main conference, but separate from the hustle and bustle of the busy conference floor.
Facilitating candid, off-record and in-depth dialogue.
Live updates & capital allocation strategies.
Pre-bookable booths to get deals done.
Ensuring seamless scheduling & efficient networking.
Plus closing drinks reception & VIP networking.
Plus post-event partner introductions delivered digitally.
Cannabis Europa brings together the brightest minds in cannabis policy, business, and investment. Over two days in London, you’ll engage with policymakers, investors, scientists, and entrepreneurs to explore opportunities in one of the world’s fastest-evolving markets.
Our speakers are global thought-leaders driving change in policy, research, and commerce. Hear their insights, challenge your thinking, and leave with actionable strategies.
From high-level policy debates to practical market strategies, Cannabis Europa London 2026 is designed to give you the knowledge and connections you need to lead.
After a period defined by rapid expansion, inflated expectations, and market correction, the cannabis industry is entering a more disciplined phase. In Europe, and particularly in the UK and Germany, the focus is shifting away from scale at any cost towards credible, healthcare-led growth. With a focus on patient access, regulatory clarity, and sustainable business models, this discussion will explore how the market is being rebuilt. It will also address where value is being created across the supply chain, how companies can align more closely with clinical outcomes, and what it takes to build trust with both regulators and patients. This is not a conversation about whether cannabis will succeed, but about how it must evolve to do so in a way that is credible, scalable, and grounded in healthcare reality. What lessons have been learned from the first wave of capital and company building, and how are those lessons shaping today's strategies?
The Road Traffic Act in the UK criminalises driving over the specified blood limit for controlled drugs, including THC, but it also creates a statutory medical defence if the medicine was lawfully prescribed and taken according to directions. Patients taking their medicine in the workplace can also present a different, equally pertinent set of issues. This general uncertainty is compounded by a lack of operational clarity across public bodies. For example, the DVLA stated in response to an FOI request that it holds no CBPM-specific medical guidance and is 'not required to investigate the effects of medication on safe driving.' Meanwhile, a Department for Transport parliamentary answer directs patients back to prescriber advice and the general drug-driving regime. This session asks what 'policy in practice' should look like when the law recognises a medical defence, but systems and institutions still struggle to apply it consistently — from roadside stops to HR decisions.
For all the growth of legal medical cannabis markets, the international framework governing the plant remains rooted in a far more restrictive era. Under the 1961 Single Convention, cannabis is permitted for medical and scientific use, yet even after the UN's 2020 decision to remove it from Schedule IV, it remains in Schedule I, leaving countries to apply some of the strictest controls in global drug policy to a medicine that is now legally prescribed across multiple jurisdictions. That contradiction is becoming harder to ignore as more patients travel with prescribed cannabis only to face seizure, uncertainty or outright criminalisation at borders. With the UN Commission on Narcotic Drugs continuing to focus on treaty implementation, international cooperation and access to controlled medicines at its March 2026 session, this discussion asks whether incremental progress is enough, or whether meaningful patient access now demands a more ambitious, top-down rethink of cannabis in international law.
Germany has done what few thought possible: built the foundations of a progressive, federally legal cannabis framework in one of the world's largest and most regulated economies. The April 2024 Cannabis Act (CanG) delivered the seismic declassification of cannabis as a narcotic, vastly increasing patient access through the removal of BtM prescriptions to Rx prescriptions and enabling near 100% digital therapy consultations. Patient numbers have increased over fourfold to 1 million+. The medical market continues to grow rapidly, supply chains are maturing, and leading German operators are building businesses with real scale. The questions now are about profitable growth and consolidation. This panel brings together leading founder operators with direct experience building in the German market, and specialist, expert advisors. The discussion will move from organic commercial strategy to consolidation, revealing views on what it takes to lead in Europe's most consequential cannabis market.
In December 2025, President Trump signed an executive order directing federal agencies to push ahead with loosening federal restrictions on cannabis, putting the issue back in the centre of the national political conversation. This fireside discussion will explore the current state of rescheduling. How much has been accomplished already by the White House, how much sits with the DEA and the courts, and what continued uncertainty means for international stakeholders watching the US from abroad? As federal reform remains unfinished, this session will examine the path forward for rescheduling medical and adult use cannabis, and what these changes would actually mean for a wide variety of stakeholders.
Europe's patchwork of pilot programmes offers a unique opportunity to build evidence-based policies. Switzerland's trials cap purchases and monitor consumption patterns; early results show high participant satisfaction and minimal public-order issues. The Netherlands' experiment includes independent research on public health, crime and nuisance. This panel will examine how regulators can harness data to design effective laws, from setting THC limits to determining distribution models. Researchers, policymakers and industry analysts will discuss data collection challenges, the role of academic partnerships, and how to translate pilot findings into scalable frameworks. The conversation will also highlight gaps in clinical evidence and the need for European clinical trials.
Germany and the UK have emerged as the defining forces in European cannabis. Together, they are driving patient growth, investment, prescribing trends and international attention at a scale unmatched anywhere else on the continent. This fireside unpacks the latest market data, import figures, patient estimates and commercial trends shaping Europe's two most dynamic cannabis economies. From Germany's explosive post-CanG expansion to the UK's rapid clinic growth and evolving regulatory landscape, this session offers a grounded look at where the real momentum lies, and what it means for operators, investors, policymakers and healthcare leaders across Europe. Expect hard numbers, sharp analysis and a clear-eyed view of the opportunities and challenges shaping the next phase of European cannabis.
After years of hype, Europe's cannabis market is finally finding its financial footing. The region's legal medical market could surpass €1.5 billion, and the UK's market alone is valued at €300 million. But institutional capital demands governance, tax compliance and reliable financial reporting. In this session, panellists from investment funds and major operators will discuss what investors look for, how valuations are evolving, and which jurisdictions are most attractive. The conversation will explore debt financing, venture capital, IPO prospects, and the growing importance of ESG metrics.
The UK cannabis market may still be tightly constrained, but that does not mean the window for entrepreneurship has closed. In many ways, the opposite is true. While broader reform remains uncertain, a growing medical market, an evolving CBD framework, renewed focus on domestic innovation and persistent gaps across supply chains are creating space for a new generation of startups to enter early and build strategically. This session explores where the real opportunities lie for founders, investors and operators looking to establish themselves in the UK today. From cultivation and product development to clinic infrastructure and patient services, panellists will examine which parts of the market remain underbuilt, where demand is outpacing delivery, and how businesses can create value under the current rules. Rather than waiting for a distant political breakthrough, this discussion asks a more immediate question: where can smart entrepreneurs plug gaps now and shape the future of the UK cannabis economy from the ground up?
After decades of federal inaction, the United States is beginning to construct a coherent regulatory framework for cannabis, and the shape it is taking has implications on both sides of the Atlantic. The proposed rescheduling of cannabis to Schedule III would formally recognise its medical value under federal law for the first time, opening new research pathways and restructuring the tax environment for operators. Separately, recent legislative changes to the federal definition of hemp, which seek to close the regulatory loophole that allowed largely unregulated intoxicating products to proliferate outside any proper framework, signal a broader move toward bringing the entire cannabinoid category under meaningful federal oversight. This session asks what that process looks like from an international perspective. As the US works through the practical and political complexity of federal cannabis reform, are there lessons for European companies navigating their own frameworks? Where do transatlantic research, manufacturing and investment relationships go from here? And as markets mature, what does genuine regulatory convergence, or divergence, mean for businesses operating across borders?
The UK cannabis story in 2026 is still defined by a stubborn gap between policy and practice. Nearly eight years after medical cannabis was rescheduled, NHS access remains limited, while private clinics continue to grow and fill the void amid increasing patient demand. At the same time, policymakers are being forced to confront a wider set of questions around what an open, modern UK cannabis framework should actually look like. This session asks a simple question: is the UK finally ready to move from caution to action? This discussion will examine whether the UK can ever realise its obvious potential within the current framework and what would need to happen for it to do so.
As the North American cannabis industry matures, global investors and strategics are increasingly turning their attention toward Europe. This session explores why Europe's regulatory structure, banking access, pharmaceutical standards, and cross-border supply chains may create a fundamentally more scalable ecosystem. Featuring perspectives from long-time cannabis investors and senior executives across tobacco, reduced-risk products, and consumer sectors (who have deployed $1B+ into the sector). The discussion will examine where capital is flowing next and why.
The Business of Cannabis Awards return for 2026, recognising the individuals and organisations driving the global cannabis industry forward. Hosted at Rivington Street, the evening welcomes 200+ senior cannabis industry professionals — roughly 70% C-suite — across ten categories spanning cultivation, innovation, clinical practice and commercial leadership. Programme: 20:00 welcome drinks and canapés · 21:00 awards presentation · 21:45 DJs and party · 00:00 close. Separately ticketed via Eventbrite; not included with a Cannabis Europa delegate pass.
What really drives high-performing cannabis — genetics, environment, or design? Starting with Prof Colin Nuckolls (Columbia University) on the science of sunlight and plant expression, this panel connects first-principle science with real-world production. Moderated by Tom Forrest (Puro New Zealand), voices from RUA Bioscience (Paul Naske), Bluelab (Jono Jones) and CannFX (Bastiaan Kramer) explore how New Zealand has emerged as a globally respected cannabis producer and agri-tech solutions provider — leveraging unique light conditions and outdoor advantages alongside deep horticultural expertise, progressive regulation, and a highly collaborative industry to deliver consistent and globally competitive cannabis products.
Exploring the rapid evolution of Greece's medicinal cannabis sector, from a market with virtually no legal patient access to an emerging ecosystem expected to serve more than 30,000 patients in the coming years. Since legalisation in 2017, Greece has experienced a seven-year regulatory buildout before the first prescriptions were finally issued in February 2024, unlocking significant market momentum, domestic production, and growing physician adoption. The session will examine how patient demand, investment, and regulatory reform are positioning Greece as one of Southern Europe's fastest-growing medicinal cannabis markets.
Across the world, a growing number of countries have introduced models that allow patients to cultivate their own cannabis for medicinal use. This session explores how patient self-sufficiency operates internationally and examines the economic, legal, and social impacts of these frameworks. Together with Beau Whitman, Callie will analyse different global approaches to home cultivation, including the financial burden of criminalising patients through policing, prosecution, and incarceration. The session will explore how governments could potentially save millions of pounds annually through the decriminalisation of patient self-sufficiency, while also reducing pressure on public services and the criminal justice system. It will also scrutinise the perceived harms associated with home cultivation and prohibition, particularly their impact on the family unit and vulnerable patients. Drawing on international examples and economic data, this talk aims to challenge outdated assumptions and bring an often-overlooked issue into open and informed discussion. This is a conversation that has been pushed aside for too long — and it is time to put it firmly on the table.
As Europe's medical cannabis market expands, questions around quality assurance, traceability, and supply chain integrity are becoming increasingly difficult to ignore. From inconsistent standards and unclear sourcing practices to growing concerns around "GMP washing," the sector faces a credibility challenge that impacts regulators, healthcare professionals, businesses, and ultimately, patients. This session brings together experts from compliance, technology, distribution, and traceability to explore how greater transparency can strengthen trust across the supply chain. The discussion will examine the role of verified data, digital infrastructure, and independent oversight in ensuring products meet the standards expected within healthcare systems. With perspectives from logistics, compliance technology, and pharmaceutical supply chain management, the panel will explore what a truly transparent cannabis supply chain should look like, why it matters commercially and clinically, and how the industry can move beyond marketing claims toward measurable accountability.
The Medical Cannabis Consumption Device Forum is an expert-led, open-discussion session designed to educate medical cannabis patients on vaporisation technologies. Participants can explore different device types, compare their pros and cons, and gain practical guidance on use, maintenance, and safety. The forum encourages peer-led conversation and shared patient experiences, while also serving as an informal feedback platform for leading vape manufacturers — helping bridge real-world patient insight with industry innovation.
Germany's medical cannabis market has entered a new phase. Price compression, oversupply and rising distribution costs are putting pressure on margins, while pharmacy access, compliance, working capital discipline and differentiated product strategies are becoming more important. This VIP briefing will look at what the German market now rewards, what it punishes, and why the next phase is likely to be shaped by consolidation, smarter supply chains and stronger market-access platforms.
As medical cannabis markets scale across Europe, a critical disconnect remains: the relationship between genetics and patient outcomes is often overlooked or misunderstood. While clinical demand continues to grow, many products entering the market are not designed with consistent therapeutic outcomes in mind. This session brings together pioneers in cannabis genetics and plant science to explore how patient needs should inform the development process from the very beginning. From strain selection and stabilisation to cultivation, processing, and final prescription, the conversation will examine where the supply chain is falling short and what must change to deliver reliable, repeatable results for patients. With perspectives from breeding, tissue culture, and commercial production, this discussion will challenge the industry to move beyond commoditisation and towards a more precise, patient-led approach to cannabis.
Telemedicine has played a central role in Europe's medical cannabis expansion, particularly in Germany where imports surpassed 200 tonnes in 2025, reinforcing the country's position as Europe's largest medical cannabis market. As the market evolves, regulators and health authorities are now taking a closer look at online prescribing and mail-order models, signalling a shift towards tighter standards and longer-term market maturity rather than unchecked expansion. This session examines what a more regulated telehealth environment could mean for patients, clinics and investors. Experts will explore how leading operators are adapting through stronger compliance frameworks, hybrid care models and new technologies designed to verify prescriptions while maintaining patient access. The discussion will also cover EU cross-border prescribing rules, the growing role of in-person consultations and how the sector can balance patient safety, accessibility and sustainable commercial growth as Europe's medical cannabis market enters its next phase.
Europe's maturing medical markets are facing serious price compression. German bulk prices have dropped significantly while EU-GMP products still command a premium. Switzerland and the UK report similar downward pressure, and oversupply looms as cultivation capacity ramps up. This panel will discuss strategies for managing slim margins: innovative cost reduction, product differentiation, branded premium segments, and long-term offtake agreements. Panellists will examine how pricing volatility impacts valuations and capital raises, and debate whether consolidation or supply-chain rationalisation will restore balance to Europe's cannabis economy.
As women increasingly turn to cannabis to manage under-treated health conditions — from endometriosis and chronic pelvic pain to sexual dysfunction and menopause symptoms — they are driving significant shifts across the sector, from policy debates and research priorities to product innovation and patient access. Women face a different set of challenges when accessing medical cannabis, from stigma and systemic barriers to a lack of products that meet their needs. The market has seen little innovation beyond high-THC and inhalation delivery methods, despite many women expressing a preference for formats that are easier to integrate into everyday life. This panel will explore the intersection of women's health and medical cannabis, examining persistent gaps in women's healthcare and the potential role that cannabis-based treatments could play in filling these. Bringing together researchers, clinicians, policymakers, and industry leaders, the discussion will examine how science, regulation, and product innovation must now evolve to better serve women's health.
For years, flower has been the defining product of Europe's medical cannabis market, valued by patients for its familiarity, fast onset and breadth of use. But as new national frameworks emerge, a different model is taking shape. Spain's incoming system is centred on standardised oral preparations made in hospital pharmacies, France is progressing with a tightly controlled medical model that also excludes raw flower, and across Europe regulators are showing growing preference for formats that look, dose and behave more like conventional medicines. This panel asks whether Europe is genuinely moving away from flower, or simply building newer markets in a more politically cautious and clinically conventional way. It will examine whether extracts, capsules, pastilles and medical devices are better suited to winning clinician trust and regulatory acceptance, and whether that comes at the expense of patient choice. From stigma and standardisation to product innovation and prescribing behaviour, this conversation explores what Europe's next generation of medical cannabis products will look like, and who gets to decide.
North America may have built the first large-scale cannabis industry, but Europe is taking a very different approach. While US and Canadian markets were driven by rapid expansion and consumer growth, Europe has placed greater emphasis on medical frameworks, compliance, infrastructure, and clinical credibility. This panel brings together leaders from across the cannabis ecosystem to explore which region is ultimately better positioned for long-term growth. From operators and market strategists to insurance and risk experts, the discussion will examine the strengths and weaknesses of European and North American companies, what investors are valuing today, and whether evidence, trust, and risk management could become Europe's greatest competitive advantages in the global cannabis industry.
The conversation doesn't end at the Barbican. We're proud to host the official Cannabis Europa afterparty on 27 May at BrewDog Waterloo, presented by Tilray Medical in partnership with Lyphe. Bringing together two of the most respected names in European medical cannabis, the evening offers an opportunity to connect beyond the conference — with complimentary food and drinks for attending delegates. Join us to unwind, exchange ideas, and celebrate two days of the industry's most important conversations. This event is exclusively for Cannabis Europa ticket holders. Registration is required, and entry will be granted upon presentation of your conference lanyard.
Despite the UK's legalisation of medical cannabis in 2018, travelling with prescribed cannabis medicines within the UK and internationally remains a complex and often uncertain process. Patients face a patchwork of regulations, inconsistent enforcement, and varying levels of understanding across domestic and international jurisdictions. In this session, Mike Morgan-Giles of the Cannabis Industry Council, and Adam Windish of British Cannabis, will introduce the CIC's newly developed Travelling with Medical Cannabis Guide. Designed to support patients, healthcare providers, and industry stakeholders, the guide outlines the key considerations, risks, and practical steps required to travel safely and legally with medical cannabis. Attendees will gain insight into the current regulatory landscape, common pitfalls patients face, and how greater clarity and standardisation could improve patient access and confidence when travelling. This session is essential for anyone working at the intersection of patient advocacy, policy, and medical cannabis access.
Dr Hana Al Hallaj explores how innovation in cannabis is shaped not simply by legalisation, but by the structure and clarity of regulation. Drawing on cross-country data, patent trends, and real-world market dynamics, she examines how different regulatory models influence product development — from basic flower to advanced pharmaceutical formulations. The session highlights where innovation truly emerges, how capital follows regulatory certainty, and what this means for investors and operators navigating global markets. It offers a grounded, strategic perspective on where the industry is heading, and how to position within it.
A forward-looking fireside conversation on the next phase of global cannabis reform. Drawing on deep expertise in international investment, regulatory strategy, and federal policy advocacy, the session will explore how governments, investors, and industry leaders can build on recent progress to create sustainable and harmonised cannabis markets worldwide. From expanding access to capital and advancing evidence-based regulation to navigating evolving international frameworks, this discussion will examine the opportunities and challenges shaping the future of the global cannabis industry.
Relm Risk Briefing: Cannabis 2026 is a global industry report by Relm Insurance in collaboration with Prohibition Partners, examining how regulation, insurance, and operational practices intersect across the evolving cannabis supply chain. Drawing on market data, case studies, and insights from operators and regulators across Europe and North America, the briefing explores the growing importance of risk management, governance, and compliance as the cannabis sector matures from emerging market to established global industry.
Join the leading voices in cannabis policy and business. We’re proud to partner with organisations at the forefront of cannabis innovation, investment, and regulation.
Interested in partnering with Cannabis Europa London 2026?
Become a partner
We’re proud to partner with organisations at the forefront of cannabis innovation, investment, and regulation.
Cannabis Europa brings together the brightest minds in cannabis policy, business, and investment. Over two days in London, you’ll engage with policymakers, investors, scientists, and entrepreneurs to explore opportunities in one of the world’s fastest-evolving markets.
A curated selection of hotels close to The Barbican, available at preferential delegate rates. Availability and pricing are updated in real time — book early to secure your preferred option.
Rates are applied automatically when booking through this portal. No discount codes required.
The debate around cannabis reform in the United Kingdom has grown more structured, more evidence-based, and more commercially significant in recent years. Yet legislative change at the national level remains absent. Understanding why — and what the realistic trajectory looks like — matters as much to investors and business leaders as it does to policymakers […]
The European cannabis landscape is entering a high-growth phase, marked by the arrival of seasoned entrepreneurs and major institutional shifts. As Cannabis Europa London 2026 approaches, the first wave of speakers has been announced, highlighting a diverse intersection of pharmaceutical innovation, global policy, and venture capital. Martin Dickie MBE & Waterside Pharmaceuticals A major highlight […]
With dedicated sessions on M&A, investment, pricing strategy and market access, Cannabis Europa London 2026 is the room where Europe’s cannabis industry does business. There are cannabis conferences, and then there are the events where decisions actually get made. Cannabis Europa London has established itself as the latter—a curated gathering of the operators, investors, policymakers […]
Germany and Poland are tightening the rules on online prescribing. The ripple effects will reshape medical cannabis access across the continent. Telemedicine didn’t just support the growth of European medical cannabis—it turbocharged it. Online consultations and e-prescriptions lowered barriers for patients, expanded clinic reach beyond urban centres, and drove a surge in imports across the […]
Subscribe to receive the latest updates on cannabis regulation, investment, and innovation in Europe.
